Li Dean Y

MRK: EVP/President Li Dean Y sold 10,235 shares at $117.52 on 2026-02-10, reducing holdings to 92,035 shares

Li Dean Y, Executive VP & President, sold 10,235 shares of Merck & Co., Inc. at $117.52, representing a -10.0% reduction in his holdings from 102,270 to 92,035 shares. The sale occurred at a price 3.9% below the 52-week high of $121.93, while the stock has appreciated 6.0% over 30 days and 28.1% over 90 days. At MRK specifically, Li's prior sell on 2024-02-09 resulted in a 90-day return of +3.8%, indicating the stock subsequently rose after that sale; his timing pattern at this ticker shows 0 of 1 prior sells were well-timed at the 90-day mark. Merck's fundamentals remain solid with $17.3B quarterly revenue, $5.8B net income, and 6.7% annual revenue growth, alongside a moderate P/E of 15.27.

Merck EVP Li Dean Y sold 15,087 shares at $118.77 on 2026-02-04, reducing holdings to 102,270 shares (12.9% decrease).

Li Dean Y, Executive VP & President of Merck & Co., executed an open-market sale of 15,087 shares for $1,791,824.15 at $118.77, trimming his position by 12.9% to 102,270 shares post-transaction. The stock has since appreciated to $121.93 (current price), up 0.0% from its 52-week high of $121.93, and has risen 12.3% over the past 30 days and 41.3% over the past 90 days. His prior sell at this ticker on 2024-02-09 occurred in a context where the stock subsequently returned +3.8% over 90 days, indicating the prior sale was not well-timed; across his broader cross-ticker trading history, his one prior sell recorded a 90-day well-timed rate of 0.00%, showing no pattern of prescient exit timing. Merck's fundamentals remain solid with $17.3B in latest quarterly revenue, $5.8B net income, 6.7% annual revenue growth, a P/E of 15.90, and a market cap of $302.6B, suggesting the sale occurred against a backdrop of stable operational and valuation metrics rather than deteriorating conditions.